cholestyramine vs raloxifene
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of cholestyramine and raloxifene. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
7 DRUG INTERACTIONS Cholestyramine : Use with raloxifene hydrochloride is not recommended. (7.3 , 12.3) 7.1 Cholestyramine Concomitant administration of cholestyramine with raloxifene hydrochloride is not recommended.
Questran
Evista
Cholestyramine is a medicine that helps lower high cholesterol levels in your blood. It works by preventing your body from absorbing cholesterol in the intestines.
Raloxifene (Evista) is a medicine that can help treat and prevent bone loss (osteoporosis) in women after menopause. It can also lower the chance of getting a certain type of breast cancer.
This medicine is used with a diet to lower high cholesterol, especially LDL cholesterol (the "bad" cholesterol). It may also help if you have high triglycerides, but it's not the best choice if high triglycerides are your main problem. Lowering cholesterol helps reduce your risk of heart disease.
This medicine is used to treat and prevent osteoporosis in women after menopause. It can also lower the risk of invasive breast cancer in women after menopause who have osteoporosis or are at high risk of getting it. This medicine is not for treating breast cancer, lowering the risk of breast cancer coming back, or lowering the risk of non-invasive breast cancer.
Cholestyramine is a resin that binds to bile acids in your intestines. Bile acids help digest fats, including cholesterol. By binding to bile acids, cholestyramine prevents them from being reabsorbed, so your body uses cholesterol to make more bile acids, which lowers cholesterol levels in your blood.
Raloxifene belongs to a class of drugs called Selective Estrogen Receptor Modulators (SERMs). It works like estrogen in some parts of the body, such as bones, which helps to prevent bone loss. But it blocks estrogen's effects in other parts of the body, like the breast, which can help prevent certain types of breast cancer.
- • Constipation
- • Hot flashes
- • Leg cramps
- • Swelling in your legs or feet
- • Flu-like symptoms
- • Joint pain
- Diarrhoea 1,631
- Fatigue 877
- Nausea 783
- Arthralgia 621
- Headache 543
- Fatigue 143
- Arthralgia 109
- Diarrhoea 109
- Fall 107
- Nausea 106
Since cholestyramine can affect how your body absorbs other medicines, take other drugs at least 1 hour before or 4 to 6 hours after taking cholestyramine.
Raloxifene can increase your risk of blood clots in your veins (deep vein thrombosis) and lungs (pulmonary embolism). If you have had blood clots in the past, you should not take this medicine. Raloxifene can also increase the risk of death from stroke in women who have heart disease or are at risk for heart problems. Talk to your doctor about the risks and benefits of taking raloxifene if you are at risk for stroke.
Tell your doctor if you are pregnant or plan to become pregnant. Cholestyramine may affect how you absorb vitamins, so your doctor may recommend supplements. Talk to your doctor about the risks and benefits of taking this medicine while breastfeeding.
You should not take this medicine if you are pregnant or could become pregnant. It may harm your unborn baby. Do not use this medicine if you are breastfeeding.
Also Compare, Nearby Drugs
Compare cholestyramine with
Compare raloxifene with
How to Read This cholestyramine vs raloxifene Comparison
cholestyramine is classified in the Bile Acid Sequestrant drug class, while raloxifene sits within the Selective Estrogen Receptor Modulator (SERM) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, cholestyramine has 4,455 submissions while raloxifene has 574. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to cholestyramine can stick to other medicines in your digestive tract and prevent them from being absorbed into your body. this makes the other medicine, like raloxifene, much less effective.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for cholestyramine or raloxifene.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.